AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$CYTK

Malik Fady Ibraham sold $264K of CYTK

Malik Fady Ibraham (EVP Research & Development) sold 3,500 shares of CYTOKINETICS INC (CYTK) at $75.46 ($0.26M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Malik Fady Ibraham
Published Sep 8, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
low confidence
Mentioned
$CYTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The sale is modest and likely reflects routine portfolio management rather than a red flag.

02

Market read

Small insider sell with limited trading relevance.

03

What to watch

Potential upcoming clinical data could offset sell pressure.

Relevance 3/10Novelty 3/10Timing: 2026-09-08 filing

Background

Form 4 filing reports an insider transaction for Cytokinetics Inc.

Company-level read

Ticker impact

$CYTKNeutralLow confidence
Context

Insider EVP R&D sold 3,500 shares for $264,110 via a 10b5-1 plan on 2026-09-08.

Expected impact

Potential slight dip as market digests insider sell.

Evidence & confidence

Sale size is small relative to float and price, unlikely to move market materially.

Market effects

Sector

Limited impact on biotech sector; typical insider sell.

Regional

No regional effect.

Global

Negligible.

Counterpoint

What could challenge this read

Insider may be diversifying; could be a buying opportunity if fundamentals remain strong.

Key entities

  • Officer
    Malik Fady Ibraham

    EVP Research & Development at Cytokinetics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min